262 related articles for article (PubMed ID: 18557422)
21. Characterization of [3H]flunitrazepam binding to melanin.
Testorf MF; Kronstrand R; Svensson SP; Lundström I; Ahlner J
Anal Biochem; 2001 Nov; 298(2):259-64. PubMed ID: 11700981
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effect of the R2 phenothiazine ring substituent on fluphenazine and perphenazine interactions with cyclodextrins.
Lutka A; Prange W
Acta Pol Pharm; 2005; 62(6):419-25. PubMed ID: 16583980
[TBL] [Abstract][Full Text] [Related]
23. Chromatographic modelling of interactions between melanin and phenothiazine and dibenzazepine drugs.
Radwańska A; Frackowiak T; Ibrahim H; Aubry AF; Kaliszan R
Biomed Chromatogr; 1995; 9(5):233-7. PubMed ID: 8593425
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of phenothiazine-type calmodulin antagonists against Mycobacterium leprae.
Dhople AM
Microbios; 1999; 98(390):113-21. PubMed ID: 10624009
[TBL] [Abstract][Full Text] [Related]
25. Interpretation of Ocular Melanin Drug Binding Assays. Alternatives to the Model of Multiple Classes of Independent Sites.
Manzanares JA; Rimpelä AK; Urtti A
Mol Pharm; 2016 Apr; 13(4):1251-7. PubMed ID: 26820602
[TBL] [Abstract][Full Text] [Related]
26. Studies of the mechanism of chloroquine binding to synthetic DOPA-melanin.
Stepień KB; Wilczok T
Biochem Pharmacol; 1982 Nov; 31(21):3359-65. PubMed ID: 6816244
[TBL] [Abstract][Full Text] [Related]
27. Oxidation causes melanin fluorescence.
Kayatz P; Thumann G; Luther TT; Jordan JF; Bartz-Schmidt KU; Esser PJ; Schraermeyer U
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):241-6. PubMed ID: 11133875
[TBL] [Abstract][Full Text] [Related]
28. Studies on the melanin affinity of haloperidol.
Lydén A; Larsson B; Lindquist NG
Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):230-43. PubMed ID: 7181580
[TBL] [Abstract][Full Text] [Related]
29. Semiconductor properties of natural melanins.
Strzelecka T
Physiol Chem Phys; 1982; 14(3):223-31. PubMed ID: 7185058
[TBL] [Abstract][Full Text] [Related]
30. Ca2+ -dependence and inhibition of transformation by trifluoperazine and chlorpromazine in Thermoactinomyces vulgaris.
Bhatnagar K; Singh VP
Curr Microbiol; 2003 Apr; 46(4):265-9. PubMed ID: 12732975
[TBL] [Abstract][Full Text] [Related]
31. Amphetamine binding to synthetic melanin and scatchard analysis of binding data.
Gautam L; Scott KS; Cole MD
J Anal Toxicol; 2005; 29(5):339-44. PubMed ID: 16105258
[TBL] [Abstract][Full Text] [Related]
32. Binding of 14C-spermidine to melanin in vivo and in vitro.
Tjälve H; Nilsson M; Larsson B
Acta Physiol Scand; 1981 Jun; 112(2):209-14. PubMed ID: 7315415
[TBL] [Abstract][Full Text] [Related]
33. LENS AND CORENEA CHANGES DURING PHENOTHIAZINE THERAPY: A PRELIMINARY REPORT.
BARSA JA; NEWTON JC; SAUNDERS JC
Am J Psychiatry; 1965 Sep; 122():331-2. PubMed ID: 14327480
[No Abstract] [Full Text] [Related]
34. Interactions of flavins with melanin. Studies on equilibrium binding of riboflavin to dopa-melanin and some spectroscopic characteristics of flavin-melanin complex.
Kozik A; Korytowski W; Sarna T; Bloom AS
Biophys Chem; 1990 Oct; 38(1-2):39-48. PubMed ID: 2128193
[TBL] [Abstract][Full Text] [Related]
35. Ultrafast energy transfer from bound tetra(4-N,N,N,N-trimethylanilinium)porphyrin to synthetic dopa and cysteinyldopa melanins.
Ye T; Simon JD; Sarna T
Photochem Photobiol; 2003 Jan; 77(1):1-4. PubMed ID: 12856874
[TBL] [Abstract][Full Text] [Related]
36. Binding of phenothiazine neuroleptics to plasma proteins.
Verbeeck RK; Cardinal JA; Hill AG; Midha KK
Biochem Pharmacol; 1983 Sep; 32(17):2565-70. PubMed ID: 6137223
[TBL] [Abstract][Full Text] [Related]
37. Retention of the cyanobacterial neurotoxin beta-N-methylamino-l-alanine in melanin and neuromelanin-containing cells--a possible link between Parkinson-dementia complex and pigmentary retinopathy.
Karlsson O; Berg C; Brittebo EB; Lindquist NG
Pigment Cell Melanoma Res; 2009 Feb; 22(1):120-30. PubMed ID: 19154235
[TBL] [Abstract][Full Text] [Related]
38. Binding of chemicals to melanins re-examined: adsorption of some drugs to the surface of melanin particles.
Bridelli MG; Ciati A; Crippa PR
Biophys Chem; 2006 Jan; 119(2):137-45. PubMed ID: 16139945
[TBL] [Abstract][Full Text] [Related]
39. Characterization of drug-protein binding process by employing equilibrium sampling through hollow-fiber supported liquid membrane and Bjerrum and Scatchard plots.
Barri T; Trtić-Petrović T; Karlsson M; Jönsson JA
J Pharm Biomed Anal; 2008 Sep; 48(1):49-56. PubMed ID: 18565712
[TBL] [Abstract][Full Text] [Related]
40. Modeling drug-melanin interaction with theoretical linear solvation energy relationships.
Lowrey AH; Famini GR; Loumbev V; Wilson LY; Tosk JM
Pigment Cell Res; 1997 Oct; 10(5):251-6. PubMed ID: 9359620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
